LMR Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

LMR Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50,000	Closed	-$1.19M	–	1338
2021 Q3	$1.19M	Sell	50,000 -45,045	-47%	-$1.06M	0.01%	592
2021 Q2	$2.33M	Sell	95,045 -3,955	-4%	-$88.2K	0.04%	332
2021 Q1	$1.81M	Buy	+99,000	New	+$2.04M	0.05%	357

Other funds holding RXDX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

LMR Partners's RXDX Position: Q4 2021 in Review

LMR Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2021, closing a stake of 50,000 shares — an estimated $1.19M sold.

LMR Partners first reported a position in RXDX in Q1 2021 and held it in 3 quarters. The position peaked at $2.33M in Q2 2021. 74 funds tracked by Wall St. Rank hold RXDX as of Q4 2021.

LMR Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
LMR Partners sold 50,000 Prometheus Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $1.19M.
LMR Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
LMR Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $2.33M in Q2 2021.
74 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.